Icosavax Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Icosavax, Inc. (ICVX)
Company Research
Source: GlobeNewswire
- Initiated a Phase 1/2 clinical trial for IVX-411, a virus-like particle (VLP) displaying the SARS-CoV-2 receptor-binding domain - - Initiated a Phase 1/1b clinical trial for IVX-121, a VLP displaying a Respiratory Syncytial Virus (RSV) stabilized pre-fusion F antigen - - Raised $209.3 million in gross proceeds from an upsized IPO, funding operations through at least 2024 - SEATTLE, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update. “The second quarter and recent period has been a transformational time for Icosavax thanks to our initiation of two clinical trials, one in RSV and one in SARS-CoV-2, as well as our successful initial p
Show less
Read more
Impact Snapshot
Event Time:
ICVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ICVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ICVX alerts
High impacting Icosavax, Inc. news events
Weekly update
A roundup of the hottest topics
ICVX
News
- M&A Funds And The Stocks Where There Is At Least A 3.5% Stake [Seeking Alpha]Seeking Alpha
- SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates ICVX, PGTI, IONMPR Newswire
- Icosavax: Tender Offer With Contingent Value Right [Seeking Alpha]Seeking Alpha
- INVESTIGATION ALERT: Halper Sadeh LLC Investigates CSTR, ICVX, BATLGlobeNewswire
- ICOSAVAX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVXPR Newswire
ICVX
Earnings
- 11/14/23 - Beat
ICVX
Sec Filings
- 2/21/24 - Form SC
- 2/21/24 - Form EFFECT
- 2/20/24 - Form 4
- ICVX's page on the SEC website